|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-6-4
|
|
pubmed:abstractText |
Hsp90alpha's vital role in cell cycle progression and apoptosis together with its presence in gliomas and absence in normal tissue, make it a credible target for cancer therapy. Three sets of dsRNA oligos designed to align different regions of the hsp90alpha sequence were used to downregulate hsp90alpha. SiRNA 1, 2, and 3 resulted in significant levels of silencing of hsp90alpha after 48 hr treatment (p < .0001). Concurrent treatment of the glioma cell line U87-MG with siRNA 1 and temozolomide (TMZ) resulted in a 13-fold reduction in the dose of TMZ required to achieve a similar effect if TMZ was used alone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/HSP90 Heat-Shock Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/HSP90alpha protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Small Interfering,
http://linkedlifedata.com/resource/pubmed/chemical/temozolomide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1532-4192
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
608-14
|
|
pubmed:meshHeading |
pubmed-meshheading:20210521-Antineoplastic Agents, Alkylating,
pubmed-meshheading:20210521-Brain Neoplasms,
pubmed-meshheading:20210521-Cell Line, Tumor,
pubmed-meshheading:20210521-Cell Survival,
pubmed-meshheading:20210521-Chemotherapy, Adjuvant,
pubmed-meshheading:20210521-Cisplatin,
pubmed-meshheading:20210521-Dacarbazine,
pubmed-meshheading:20210521-Dose-Response Relationship, Drug,
pubmed-meshheading:20210521-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:20210521-Gene Therapy,
pubmed-meshheading:20210521-Glioma,
pubmed-meshheading:20210521-HSP90 Heat-Shock Proteins,
pubmed-meshheading:20210521-Humans,
pubmed-meshheading:20210521-Inhibitory Concentration 50,
pubmed-meshheading:20210521-RNA, Messenger,
pubmed-meshheading:20210521-RNA, Small Interfering,
pubmed-meshheading:20210521-RNA Interference,
pubmed-meshheading:20210521-Time Factors,
pubmed-meshheading:20210521-Transfection
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
|
|
pubmed:affiliation |
Brain Tumour North West, Faculty of Science and Technology, University of Central Lancashire, Preston, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
